Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-08-29
2009-08-11
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
Reexamination Certificate
active
07572777
ABSTRACT:
The present invention discloses methods of using phosphate esters of florfenicol (prodrugs) and florfenicol analogs having superior water solubility that are hydrolyzed to florfenicol or the respective florfenicol analog in vivo, upon administration to an animal.
REFERENCES:
patent: 2776992 (1957-01-01), Gregory
patent: 4235892 (1980-11-01), Nagabhushan
patent: 5352832 (1994-10-01), Wu et al.
patent: 7153842 (2006-12-01), Hecker et al.
patent: 2004/0082553 (2004-04-01), Boojamra et al.
patent: 2005/0182139 (2005-08-01), Shuster et al.
patent: 2 418 102 (2002-12-01), None
patent: 2 422 359 (2008-12-01), None
patent: 0 014 437 (1980-08-01), None
patent: WO 03/077828 (2003-09-01), None
patent: WO 2005/009429 (2005-02-01), None
Bolton, Lance F., et al., “Detection of Multidrug-Resistant . . . ,” Journal of Clinical Microbiology 37(5):1348-1351 (May 1999).
Cloeckaert, Axel, et al., “Nonenzymatic Chloramphenicol Resistance Mediated . . . ,” Antimicrobial Agents and Chemotherapy 45(8):2381-2382 (Aug. 2001).
Keyes, Kathleen, et al., “Detection of Florfenicol Resistance Genes . . . ,” Antimicrobial Agents and Chemotherapy 44(2):421-424 (Feb. 2000).
Kim, Eun-Heul, et al., “Sequence Analysis of the Florfenicol Resistance . . . ,” Microbiol. Immunol. 40(9):665-669 (1996).
PCT International Search Report dated Jun. 28, 2005 for corresponding PCT Application No. PCT/US2004/042591.
Hu, Z., “Pharmaceutical Chemistry”, People's Medical Publishing House, Fourth Ed., p. 476; (Jul. 2002). (In Chinese language only).
Kong, A. et al., “Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination”,J Pharm Sci, 80(5): 409-415 (1991).
Kramer, WG et al., “Comparative bloavailability of intravenous and oral chloramphenicol in adults”,J. Clin Pharmacol24(4):181-186 (1984).
Ti, T. et al., “Chloramphenical Concentrations in Sera of Patients with Typhoid Fever Being Treated with Oral or Intravenous Preparation”,Antimicrobial Agents and Chemotherapy, 34(9):1809-1811 (1990).
Hu Zheng., “Pharmaceutical Chemistry”, People's Medical Publishing House (Junction 67616688), Fourth Ed., p. 476; (Jul. 2002). (English Translation).
Banaszczyk, M. G., et al., “Propofol Phosphate, a Water-Soluble Propofol Prodrug: In Vivo Evaluation”,Anesth Analog95:1285-1292 (2002).
Schmatz, D. M., et al., “Antipneumocystis Activity of Water-Soluble Lipopeptide L-693,989 in Rats”,Antimicrobial Agents and Chemotherapy, 36(9):1964-1970 (1992).
Glinka Tomasz W.
Hecker Scott J.
Pansare Sunil V.
Anderson Rebecca L
Kerwick David J.
Nolan Jason
Schering-Plough Animal Health Corp.
LandOfFree
Florfenicol prodrug having improved water solubility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Florfenicol prodrug having improved water solubility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Florfenicol prodrug having improved water solubility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095181